Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Published

Effect of Psilocybin on Empathy and Moral Decision-Making.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal
The international journal of neuropsychopharmacology
Date
2017-09-01
Source
PubMed
DOI
10.1093/ijnp/pyx047
PubMed
28637246

Authors

Pokorny TPreller KHKometer MDziobek IVollenweider FX
Watch author

Derived topics and classifications

psilocybin Receptor PharmacologyEmotional Processing Other

Citation graph

0 referenced DOIs found in stored source metadata. 3 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants2026-07-01Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy2026-03-01Effect of Psilocybin on Empathy and Moral Decision-Making.2017-09-01

Related papers

Psychedelics and autism spectrum disorder: Mechanistic insights, translational evidence and ethical challenges.Journal of psychiatric research · 2026-10-01Targeting the serotonin 1B receptor for the treatment of depression and anxiety.Expert opinion on therapeutic targets · 2026-09-28Exploring the Therapeutic Potential of Psilocybin: A Comprehensive Review of Clinical Trial Evidence and Implications for Rescheduling.Mini reviews in medicinal chemistry · 2026-09-18Correlation of Ketamine and Classic Psychedelics with Pain-Related Neural Connectivity: A Scoping Review of Clinical Experiments on a Potential Therapeutic Target Concerning Ketamine and Classical Psychedelics Administration for Pain ReliefPsychedelic Medicine · 2026-09-14Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's DiseaseClinicalTrials.gov · 2026-09-04Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseClinicalTrials.gov · 2026-10-02Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2026-10-01PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-10-01